Valsartan MDL Defendant ZHP Opposes Special Master’s Discovery Sanctions Order




CAMDEN, N.J. — Valsartan drugs MDL defendant Zhejiang Huahai Pharmaceutical Company Ltd. (ZHP) has opposed a special master’s order that it be sanctioned for violating an order compelling its CEO to appear for a deposition, arguing that it “acted in good faith and with reasonable diligence” to secure his presence for the deposition.

In a May 31 motion, ZHP further contends that it produced documents that Hon. Thomas I. Vanaskie (Ret.) found remain outstanding, and that the sanctions he proposed are “excessive and unjust.”

The lawsuits accuse ZHP and other drug manufacturers of selling valsartan-containing drugs that they knew …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference

July 24, 2024 - Portland, ME
The Westin Portland Harborview

MORE DETAILS



HarrisMartin's Midwest Asbestos Litigation Conference

September 27, 2024 - St. Louis, MO
Four Seasons Hotel, St. Louis

MORE DETAILS